Pharma Mar S.A. is a leading biopharmaceutical company based in Spain, focused on the discovery and development of innovative marine-based drugs for oncology purposes. Harnessing compounds derived fro... Pharma Mar S.A. is a leading biopharmaceutical company based in Spain, focused on the discovery and development of innovative marine-based drugs for oncology purposes. Harnessing compounds derived from the sea, Pharma Mar aims to treat various forms of cancer with novel therapies. The company’s commitment to leveraging unique marine ecosystems has led to the development of several proprietary anticancer products that contribute to breakthroughs in medical treatments.
Pharma Mar operates across the globe, distributing its products through its extensive network in key international markets. The company not only plays a pivotal role in the oncology sector but also invests in continuous research and development to uphold its competitive edge in marine biotechnology. Through strategic partnerships and collaborations with leading research institutions and universities, Pharma Mar strives to expand its pipeline and explore further therapeutic applications of marine-derived compounds. In the financial markets, Pharma Mar is recognized for its innovation-driven approach and the specialized niche it occupies, making it a vital entity in advancing cancer treatment solutions.
In 2024, Pharma Mar was subject to the Corporate Sustainability Reporting Directive (CSRD)'s requirements, which mandated the company to publish EU Taxonomy disclosures.
The company reported the eligibility and alignment of Turnover, Capital Expenditure (CAPEX) and Operating Expenditure (OPEX) with the EU Taxonomy, helping assess the extent to which its business activities align with Europe's environmental sustainability goals.
Pharma Mar has also provided an activity-level breakdown of its EU Taxonomy disclosures. This granular reporting enhances transparency around which economic activities of Pharma Mar are considered environmentally sustainable and contribute to at least one of the six environmental objectives defined under the EU Taxonomy framework.
Metric (tonnes)
2024
2023
2022
2021 - 2017
Total Taxonomy Aligned A1 Turnover
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
c
0000000
Total Taxonomy Eligible A Turnover
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
c
0000000
Total Taxonomy Non-Eligible B Turnover
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
c
0000000
Metric (tonnes)
2024
2023
2022
2021 - 2017
Total Taxonomy Aligned A1 Opex
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
c
0000000
Total Taxonomy Eligible A Opex
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
c
0000000
Total Taxonomy Non-Eligible B Opex
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
c
0000000
Metric (tonnes)
2024
2023
2022
2021 - 2017
Total Taxonomy Aligned A1 Capex
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
c
0000000
Total Taxonomy Eligible A Capex
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
c
0000000
Total Taxonomy Non-Eligible B Capex
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
c
0000000
7.6 CCM/CCA - Installation, maintenance and repair of renewable energy technologies
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
Copy/Paste is a PRO feature.
0000000
Limited Data Preview
You are viewing a limited preview of Pharma Mar’s EU Taxonomy dataset. The full dataset, available for download, includes eligibility and alignment metrics for turnover, CAPEX, and OPEX across all EU Taxonomy categories (A1, A2, A, B, and A+B), at both aggregate and activity level, with historical coverage back to 2021.
Access Datasets, Disclosures, and Sources
pro
Remove manual data sourcing from your workflow. Subscribe to Tracenable Pro to get credits for accessing and exporting datasets and disclosures across 8,500+ companies with 10+ years of historical coverage.
Used by 1,000+ teams in finance, climate, and research
Verified Sources Behind Pharma Mar’s EU Taxonomy Data
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Pharma Mar’s data sources below and access millions more through our Disclosure Search.
a. Pharma Mar's Annual Report 2024
b. Pharma Mar's Consolidated Non-Financial Report 2023
c. Pharma Mar's Consolidated Non-Financial Report 2022
Insights into Pharma Mar's Revenues from Sustainable Activities
In 2024, Pharma Mar reported EU Taxonomy-eligible revenues of EUR 66.54 million, representing 38.1% of its total turnover. Of this amount, EUR 0 of Pharma Mar's revenues was classified as EU Taxonomy-aligned, indicating that 0% of the revenue-generating activities undertaken by the company substantially contribute to one or more of the six environmental objectives, meet the Do No Significant Harm (DNSH) criteria, and comply with the Minimum Social Safeguards (MSS).a
Insights into Pharma Mar's CAPEX from Sustainable Activities
In 2024, Pharma Mar reported EU Taxonomy-eligible CAPEX of EUR 1.02 million,representing 5.8% of its total CAPEX. Of this amount, EUR 85,000 of Pharma Mar's CAPEX was classified as EU Taxonomy-aligned, indicating that 0.5% of the company's investments were directed toward economic activities that substantially contribute to one or more of the six environmental objectives, meet the Do No Significant Harm (DNSH) criteria, and comply with the Minimum Social Safeguards (MSS).a
How much of Pharma Mar's capital expenditure (CAPEX) is eligible under the EU Taxonomy?
In 2024, Pharma Mar reported that EUR 1.02 million of its capital expenditure (CAPEX) was eligible under the EU Taxonomy, representing 5.8% of the company's total CAPEX. Of this amount, EUR 85,000 (0.5% of total CAPEX) was classified as Taxonomy-aligned. This means that 5.3% of Pharma Mar's CAPEX is eligible but not aligned, indicating that these investments either did not meet the technical screening criteria, failed to comply with the Do No Significant Harm (DNSH) requirements, or lacked evidence of meeting the Minimum Safeguards (MSS).a
How much of Pharma Mar's eligible CAPEX is aligned with the EU Taxonomy?
In 2024, Pharma Mar reported that EUR 85,000 of its CAPEX was aligned under the EU Taxonomy, representing 0.5% of its total capital investment.a
This low alignment reflects that Pharma Mar is beginning to transition its capital allocation toward greener investments, but still retains substantial opportunities for further alignment with sustainability goals.
Pharma Mar's Eligibility & Alignment Overview
Pharma Mar's Contribution to Environmental Objectives
Total Taxonomy Aligned A1 Capex
Total Taxonomy Eligible but Not Aligned A2 Capex
How is Pharma Mar's taxonomy-aligned CAPEX distributed across the EU environmental objectives?
In 2024, Pharma Mar reported that its taxonomy-aligned capital expenditure (CAPEX) was distributed across the following EU environmental objectivesa:
Climate Change Mitigation: 0.5%
Climate Change Adaptation: 0%
Sustainable Use and Protection of Water and Marine Resources: 0%
Transition to a Circular Economy: 0%
Pollution Prevention and Control: 0%
Protection and restoration of biodiversity and ecosystems: 0%
How much Pharma Mar is investing in climate-related solutions?
In 2024, Pharma Mar allocated EUR 87,810 of its CAPEX to activities contributing to the EU Taxonomy's climate-related objectives (Climate Change Mitigation and Climate Change Adaptation). This represented 0.5% of the company's total capital expenditure,indicating that Pharma Marhas only marginally directed its capital expenditure toward climate-related activities, suggesting limited alignment with climate objectives.a
Insights into Pharma Mar's OPEX from Sustainable Activities
In 2024, Pharma Mar reported EU Taxonomy-eligible OPEX of EUR 153,000,representing 0.1% of its total operating expenses (OPEX). Of this amount, EUR 3,000 of Pharma Mar's OPEX was classified as EU Taxonomy-aligned, indicating that 0% of the company's operating expenses were directed toward economic activities that substantially contribute to one or more of the six environmental objectives, meet the Do No Significant Harm (DNSH) criteria, and comply with the Minimum Social Safeguards (MSS).a
Pharma Mar's Contribution to Environmental Objectives
Total Taxonomy Aligned A1 Opex
Total Taxonomy Eligible but Not Aligned A2 Opex
How is Pharma Mar's taxonomy-aligned OPEX distributed across the EU environmental objectives?
In 2024, Pharma Mar reported that its taxonomy-aligned operational expenditure (OPEX) was distributed across the following EU environmental objectivesa:
Climate Change Mitigation: 0%
Climate Change Adaptation: 0%
Sustainable Use and Protection of Water and Marine Resources: 0%
Transition to a Circular Economy: 0%
Pollution Prevention and Control: 0%
Protection and restoration of biodiversity and ecosystems: 0%
How much of Pharma Mar's operational budget supports climate-related solutions?
In 2024, Pharma Mar allocated EUR 0 of its OPEX to activities contributing to the EU Taxonomy's climate-related objectives (Climate Change Mitigation and Climate Change Adaptation). This represented 0% of the company's total OPEX,indicating that Pharma Marhas only a limited share of operational expenditure aligned with climate goals, signaling early-stage or minimal integration of climate objectives into its routine activities.a
Want Full Access to Pharma Mar's EU Taxonomy Dataset?
b
b
a
b
c
b
a
b
b
c
a
b
c
a